Results 21 to 30 of about 6,667,826 (304)

Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers

Frontiers in Oncology, 2022
Simple summaryLow-grade serous ovarian cancer (LGSOC) represents an uncommon histotype of serous ovarian cancer (accounting for approximately 5% of all ovarian cancer) with a distinct behavior compared to its high-grade serous counterpart, characterized ...
Paolo Di Lorenzo, Paolo Di Lorenzo, Vincenza Conteduca, Vincenza Conteduca, Emanuela Scarpi, Marco Adorni, Francesco Multinu, Annalisa Garbi, Ilaria Betella, Tommaso Grassi, Tommaso Bianchi, Giampaolo Di Martino, Andrea Amadori, Paolo Maniglio, Isabella Strada, Silvestro Carinelli, Marta Jaconi, Giovanni Aletti, Giovanni Aletti, Vanna Zanagnolo, Angelo Maggioni, Luca Savelli, Ugo De Giorgi, Fabio Landoni, Nicoletta Colombo, Nicoletta Colombo, Robert Fruscio, Robert Fruscio   +27 more
doaj   +1 more source

Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse [PDF]

, 2012
This report describes the clinical courses of two acute myeloid leukemia patients. Both had MLL translocations, the first a t(10;11)(p11.2;q23) with MLL-AF10 and the second a t(11;19)(q23;p13.1) with MLL-ELL fusion.
Meyer, Claus, Carola Tietze-Bürger, Claus Meyer, Igor Blau, Burmeister, Thomas, Molkentin, Mara, Thomas Burmeister, Mara Molkentin, Nils Lachmann, Uharek, Lutz, Rolf Marschalek, Tietze-Bürger, Carola, Friedrichs, Birte, Blau, Igor Wolfgang, Jörg Beyer, Marschalek, Rolf, Schwartz, Stefan, Lutz Uharek, Beyer, Jörg, Stefan Schwartz, Gunnar Lohm, Birte Friedrichs, Lachmann, Nils, Lohm, Gunnar   +23 more
core   +1 more source

Minimal residual disease [PDF]

Current Opinion in Hematology, 1999
Monitoring of residual disease in patients with malignant hematologic disorders has been recognized as an important diagnostic tool for assessment of the response to treatment and the individual risk of relapse. In a number of malignancies, employment of sensitive techniques permitting the identification of tumor cells within a 10(4)-fold or greater ...
openaire   +3 more sources

Predictors of residual disease after debulking surgery in advanced stage ovarian cancer

Frontiers in Oncology, 2023
ObjectiveOptimal debulking with no macroscopic residual disease strongly predicts ovarian cancer survival. The ability to predict likelihood of optimal debulking, which may be partially dependent on tumor biology, could inform clinical decision-making ...
Farnoosh Abbas-Aghababazadeh, Farnoosh Abbas-Aghababazadeh, Naoko Sasamoto, Mary K. Townsend, Tianyi Huang, Kathryn L. Terry, Allison F. Vitonis, Kevin M. Elias, Elizabeth M. Poole, Jonathan L. Hecht, Shelley S. Tworoger, Brooke L. Fridley   +11 more
doaj   +1 more source

Short‐term efficacy and long‐term survival of nasopharyngeal carcinoma patients with radiographically visible residual disease following observation or additional intervention: A real‐world study in China

Laryngoscope Investigative Otolaryngology, 2022
Background To explore the short‐ and long‐term outcomes in patients with nasopharyngeal carcinoma (NPC) with magnetic resonance imaging (MRI)‐detected residual disease at 3 months post‐treatment who received intervention either promptly (0 month) or ...
Ying‐Ying Huang, Xun Cao, Zhuo‐Chen Cai, Jia‐Yu Zhou, Xiang Guo, Xing Lv   +5 more
doaj   +1 more source

Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients

Frontiers in Oncology, 2023
IntroductionPrimary debulking surgery (PDS), interval debulking surgery (IDS), and platinum-based chemotherapy are the current standard treatments for advanced ovarian cancer (OC).
Alberto Farolfi, Elisabetta Petracci, Giorgia Gurioli, Gianluca Tedaldi, Claudia Casanova, Valentina Arcangeli, Andrea Amadori, Marta Rosati, Marco Stefanetti, Salvatore Luca Burgio, Maria Concetta Cursano, Cristian Lolli, Valentina Zampiga, Ilaria Cangini, Giuseppe Schepisi, Ugo De Giorgi   +15 more
doaj   +1 more source

Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? [PDF]

Open Biology, 2012
Although chemotherapy of tumours has scored successes, drug resistance remains the major cause of death of cancer patients. Initial treatment often leaves residual disease, from which the tumour regrows.
Piet Borst
doaj   +1 more source

The impact of different sprayable surfaces on the effectiveness of indoor residual spraying using a micro encapsulated formulation of lambda-cyhalothrin against Anopheles gambiae s.s [PDF]

, 2015
The type of sprayable surface impacts on residual efficacy of insecticide used in indoor residual spraying (IRS). However, there is limited data on common types of wall surfaces sprayed in Zanzibar and mainland Tanzania where IRS began in 2006 and 2007 ...
Jasper N Ijumba, Mwalimu, Charles D., Mwaipape, Osia, Juma G Rutta, Frances E Mugarula, Thawer, Narjis G., Stephen M Magesa, Jeremiah M Ngondi, Ramsan, Mahdi M., Ijumba, Jasper N., Fabrizio Molteni, Mahdi M Ramsan, Pratap, Harish B., Rutta, Juma G., Harish B Pratap, Molteni, Fabrizio, Narjis G Thawer, Ngondi, Jeremiah M., Mutagahywa, Joshua, Elias C Nyanza, Kafuko, Jessica M., Nyanza, Elias C., Reithinger, Richard, Mugarula, Frances E., Magesa, Stephen M., Osia Mwaipape, Isaiah Ndong, Charles D Mwalimu, Richard Reithinger, Jessica M Kafuko, Joshua Mutagahywa, Ndong, Isaiah   +31 more
core   +1 more source

Efficacy and Safety of Local Radiotherapy to All Oligometastatic Sites in Elderly Patients with Metachronous Oligometastatic Cancers After Initial Treatment for the Primary Tumor

Cancer Management and Research, 2021
Xiaolong Hu,1 Hongqi Li,2 Xiaoli Kang,2 Xuan Wang,2 Haifeng Pang,2 Chen Liu,2 Jianchun Zhang,1 Yingjie Wang2 1Department of Radiation Oncology, Beijing Geriatric Hospital, Beijing, People’s Republic of China; 2Department of Radiation Oncology, Air Force ...
Hu X, Li H, Kang X, Wang X, Pang H, Liu C, Zhang J, Wang Y   +7 more
doaj  

Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer

Current Oncology, 2022
Breast cancer continues to be the most diagnosed cancer among women worldwide. Neoadjuvant chemotherapy is the standard of care for breast cancer patients with locally advanced disease and patients with poor pathological features, such as triple-negative
Hikmat Abdel-Razeq, Hanan Khalil, Hazem I. Assi, Tarek Bou Dargham   +3 more
doaj   +1 more source